Thursday 11 December 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Europeans more interested in medical/ health research than economic/social news

Europeans more interested in medical/ health research than economic/social news

30 September 2007

People in the European Union are more interested in the results of medical and health research than in international, economic and social news, according to a new Eurobarometer report.

A survey conducted for the European Commission by Eurobarometer confirms that there is a strong interest in most European countries, particularly in the old European Union member states, in health research as well as in science and technology. The interest is even higher than in international news and economic and social affairs, it notes.

Europeans are especially paying attention to the added value that health and medical research can bring to their daily lives. The survey indicates also that citizens trust the scientific and medical professions above all others when it comes to information on science or health research, and that international institutions - including the European Union itself - are significantly more trusted than regional or national governmental sources.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

$84 million Series B extension takes BlossomHill’s fundraising beyond $257 million
Pharmaceutical
$84 million Series B extension takes BlossomHill’s fundraising beyond $257 million
10 December 2025
Biotechnology
EpilepsyGTx’s $33 million Series A to advance single dose gene therapy for focal refractory epilepsy
10 December 2025
Biotechnology
Formation Bio licenses CNS penetrant TYK2 inhibitor from Lynk Pharma
10 December 2025
Pharmaceutical
UK VPAG payment rate for newer medicines will be 14.5% in 2026
10 December 2025
Biotechnology
Tecvayli and Darzalex combination delivers in RRMM
10 December 2025
Biotechnology
D3 Bio bags $108 million in Series B financing
10 December 2025
Pharmaceutical
New data underscores aprocitentan’s potential in managing hypertension in patients with CKD
10 December 2025

Company Spotlight

Ascletis Pharmaceuticals
A fully integrated, R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.HK). The group’s operations are centered in China, with key sites in Hangzhou (including its Hangzhou-based biotech entity) and Shaoxing, supporting an integrated value chain spanning discovery and development through GMP manufacturing.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze